Form 4: RAPT Therapeutics CFO Granted Over 118,000 Stock Options

RAPT Therapeutics, Inc. Chief Financial Officer Rodney Young was granted 118,750 employee stock options with a vesting schedule commencing June 20, 2025.

Summary

• Rodney Young, Chief Financial Officer of RAPT Therapeutics, Inc. (RAPT), was granted 118,750 employee stock options.
• The options have an exercise price of $7.43 per share.
• Vesting for the options commences on June 20, 2025, with 1/48th of the shares vesting on each monthly anniversary thereafter.
• The options are exercisable and expire on June 19, 2035.
• Following this transaction, Mr. Young beneficially owns 118,750 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive, as the grant of stock options to a key executive is a standard practice that aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.

Future Outlook

This document is a report of an insider transaction and does not contain forward-looking statements regarding the company's financial performance or strategic outlook.

Industry Context

The grant of stock options to key executives like the CFO is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive compensation packages designed to attract, retain, and incentivize talent.

Related Party Transactions

• The grant of 118,750 employee stock options to Rodney Young, the Chief Financial Officer, constitutes a transaction between the company and a related party (an insider) as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CFO's financial interests with long-term shareholder value creation, potentially benefiting shareholders if the company's stock price increases.
• Employees: This transaction is specific to a key executive and does not directly impact the broader employee base, though it reflects standard executive compensation practices.

Next Steps

• The granted stock options will vest monthly over a 48-month period, commencing June 20, 2025.

Key Dates

Keywords

RAPT Therapeutics, Stock Option Grant, Executive Compensation, Rodney Young, CFO, SEC Form 4, Insider Transaction, Equity Compensation